

## REFERENCES

---

- Abunasra H, Lewis S, Beggs L, et al. (2005). Predictors of operative death after oesophagectomy for carcinoma. *Br J Surg* **92** 1029-33.
- Acker T, Diez-Juan A, Aragonés J, et al. (2005). Genetic evidence for a tumor suppressor role of HIF-2alpha. *Cancer Cell* **8** 131-41.
- Acs G, Acs P, Beckwith SM, et al. (2001). Erythropoietin and erythropoietin receptor expression in human cancer. *Cancer Res* **61** 3561-5.
- Acs G, Xu X, Chu C, et al. (2004). Prognostic significance of erythropoietin expression in human endometrial carcinoma. *Cancer* **100** 2376-86.
- Acs G, Zhang PJ, McGrath CM, et al. (2003). Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. *Am J Pathol* **162** 1789-806.
- Acs G, Zhang PJ, Rebbeck TR, et al. (2002). Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. *Cancer* **95** 969-81.
- Adachi Y, Shiraishi N, Suematsu T, et al. (2000). Most important lymph node information in gastric cancer: multivariate prognostic study. *Ann Surg Oncol* **7** 503-7.
- Adam IJ, Mohamdee MO, Martin IG, et al. (1994). Role of circumferential margin involvement in the local recurrence of rectal cancer. *Lancet* **344** 707-11.
- Adam MF, Gabalski EC, Bloch DA, et al. (1999). Tissue oxygen distribution in head and neck cancer patients. *Head Neck* **21** 146-53.
- Aebersold DM, Burri P, Beer KT, et al. (2001). Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. *Cancer Res* **61** 2911-6.
- Aikou T, Natugoe S, Tenabe G, et al. (1987). Lymph drainage originating from the lower esophagus and gastric cardia as measured by radioisotope uptake in the regional lymph nodes following lymphoscintigraphy. *Lymphology* **20** 145-51.
- Airley RE, Loncaster J, Raleigh JA, et al. (2003). GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. *Int J Cancer* **104** 85-91.
- Akre K, Ekstrom AM, Signorello LB, et al. (2001). Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. *Br J Cancer* **84** 965-8.
- Al-Kasspoles MF, Hill HC, Nava HR, et al. (2002). High-grade dysplasia within Barrett's esophagus: controversies regarding clinical opinions and approaches. *Ann Surg Oncol* **9** 222-7.
- Allum WH, Griffin SM, Watson A, et al. (2002). Guidelines for the management of oesophageal and gastric cancer. *Gut* **50 Suppl 5** v1-23.
- Altorki N (2005). En-bloc esophagectomy--the three-field dissection. *Surg Clin North Am* **85** 611-9, xi.
- Anikin VA, McManus KG, Graham AN, et al. (1997). Total thoracic esophagectomy for esophageal cancer. *J Am Coll Surg* **185** 525-9.
- Arnott SJ, Duncan W, Gignoux M, et al. (1998). Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). *Int J Radiat Oncol Biol Phys* **41** 579-83.
- AUGIS (2004). The Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland: Second Database Report 2004. Henley-on-Thames, Oxfordshire, Dendrite Clinical Systems Ltd.
- Auvinen MI, Sihvo EI, Ruohtula T, et al. (2002). Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. *J Clin Oncol* **20** 2971-9.
- Bachmann MO, Alderson D, Edwards D, et al. (2002). Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. *Br J Surg* **89** 914-22.
- Bacon AL and Harris AL (2004). Hypoxia-inducible factors and hypoxic cell death in tumour physiology. *Ann Med* **36** 530-9.
- Bani-Hani K, Martin IG, Hardie LJ, et al. (2000). Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. *J Natl Cancer Inst* **92** 1316-21.
- Bani-Hani KE, Bani-Hani BK and Martin IG (2005). Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma. *World J Gastroenterol* **11** 6807-14.
- Bardos JI and Ashcroft M (2004). Hypoxia-inducible factor-1 and oncogenic signalling. *Bioessays* **26** 262-9.
- Bartels H, Stein HJ and Siewert JR (1998). Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. *Br J Surg* **85** 840-4.

- Bates BA, Detterbeck FC, Bernard SA, et al. (1996). Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. *J Clin Oncol* **14** 156-63.
- Bax DA, Siersema PD, Van Vliet AH, et al. (2005). Molecular alterations during development of esophageal adenocarcinoma. *J Surg Oncol* **92** 89-98; discussion 99.
- Beasley NJ, Leek R, Alam M, et al. (2002). Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. *Cancer Res* **62** 2493-7.
- Beasley NJ, Wykoff CC, Watson PH, et al. (2001). Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. *Cancer Res* **61** 5262-7.
- Bedford JS and Mitchell JB (1974). The effect of hypoxia on the growth and radiation response of mammalian cells in culture. *Br J Radiol* **47** 687-96.
- Begg AC, Janssen H, Sprong D, et al. (2001). Hypoxia and perfusion measurements in human tumors--initial experience with pimonidazole and IUdR. *Acta Oncol* **40** 924-8.
- Berger AC, Farma J, Scott WJ, et al. (2005). Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. *J Clin Oncol* **23** 4330-7.
- Bergman JJ and Tytgat GN (2005). New developments in the endoscopic surveillance of Barrett's oesophagus. *Gut* **54 Suppl 1** i38-42.
- Bertheau P, Cazals-Hatem D, Meignin V, et al. (1998). Variability of immunohistochemical reactivity on stored paraffin slides. *J Clin Pathol* **51** 370-4.
- Bhutani MS, Barde CJ, Markert RJ, et al. (2002). Length of esophageal cancer and degree of luminal stenosis during upper endoscopy predict T stage by endoscopic ultrasound. *Endoscopy* **34** 461-3.
- Birner P, Gatterbauer B, Oberhuber G, et al. (2001a). Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. *Cancer* **92** 165-71.
- Birner P, Schindl M, Obermair A, et al. (2001b). Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. *Clin Cancer Res* **7** 1661-8.
- Birner P, Schindl M, Obermair A, et al. (2000). Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. *Cancer Res* **60** 4693-6.
- Blackshaw GR, Barry JD, Edwards P, et al. (2003). Open-access gastroscopy is associated with improved outcomes in gastric cancer. *Eur J Gastroenterol Hepatol* **15** 1333-7.
- Blackshaw GR, Stephens MR, Lewis WG, et al. (2004). Prognostic significance of acute presentation with emergency complications of gastric cancer. *Gastric Cancer* **7** 91-6.
- Blaser MJ (1999). Hypothesis: the changing relationships of *Helicobacter pylori* and humans: implications for health and disease. *J Infect Dis* **179** 1523-30.
- Blot WJ, Devesa SS, Kneller RW, et al. (1991). Rising incidence of adenocarcinoma of the esophagus and gastric cardia. *Jama* **265** 1287-9.
- Bonavina L, Incarbone R, Saino G, et al. (2003). Clinical outcome and survival after esophagectomy for carcinoma in elderly patients. *Dis Esophagus* **16** 90-3.
- Bonenkamp JJ, Hermans J, Sasako M, et al. (1999). Extended lymph-node dissection for gastric cancer. *N Engl J Med* **340** 908-14.
- Bos R, van der Groep P, Greijer AE, et al. (2003). Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. *Cancer* **97** 1573-81.
- Bos R, Zhong H, Hanrahan CF, et al. (2001). Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. *J Natl Cancer Inst* **93** 309-14.
- Bosari S, Lee AK, DeLellis RA, et al. (1992). Microvessel quantitation and prognosis in invasive breast carcinoma. *Hum Pathol* **23** 755-61.
- Bosset JF, Gignoux M, Triboulet JP, et al. (1997). Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. *N Engl J Med* **337** 161-7.
- Bossi P, Viale G, Lee AK, et al. (1995). Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. *Cancer Res* **55** 5049-53.
- Bramble MG, Suvakovic Z and Hungin AP (2000). Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. *Gut* **46** 464-7.
- Branagan G and Davies N (2004). Early impact of centralization of oesophageal cancer surgery services. *Br J Surg* **91** 1630-2.
- Brenner H, Arndt V, Stegmaier C, et al. (2004). Is *Helicobacter pylori* infection a necessary condition for noncardia gastric cancer? *Am J Epidemiol* **159** 252-8.

- Brizel DM, Dodge RK, Clough RW, et al. (1999). Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. *Radiother Oncol* **53** 113-7.
- Brizel DM, Rosner GL, Harrelson J, et al. (1994). Pretreatment oxygenation profiles of human soft tissue sarcomas. *Int J Radiat Oncol Biol Phys* **30** 635-42.
- Brizel DM, Scully SP, Harrelson JM, et al. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. *Cancer Res* **56** 941-3.
- Brown JM (1999). The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. *Cancer Res* **59** 5863-70.
- Brown RS, Goodman TM, Zasadny KR, et al. (2002). Expression of hexokinase II and Glut-1 in untreated human breast cancer. *Nucl Med Biol* **29** 443-53.
- Brown RS and Wahl RL (1993). Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. *Cancer* **72** 2979-85.
- BSG, Ed. (2005). Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus, British Society of Gastroenterology. <http://www.bsg.org.uk>
- Burri P, Djonov V, Aebersold DM, et al. (2003). Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. *Int J Radiat Oncol Biol Phys* **56** 494-501.
- Burroughs SH, Biffin AH, Pye JK, et al. (1999). Oesophageal and gastric cancer pathology reporting: a regional audit. *J Clin Pathol* **52** 435-9.
- Buskens CJ, Van Rees BP, Sivula A, et al. (2002). Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. *Gastroenterology* **122** 1800-7.
- Byrne JP, Mathers JM, Parry JM, et al. (2002). Site distribution of oesophagogastric cancer. *J Clin Pathol* **55** 191-4.
- Cameron AJ, Lomboy CT, Pera M, et al. (1995). Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. *Gastroenterology* **109** 1541-6.
- Caputo R, Tuccillo C, Manzo BA, et al. (2003). Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. *Clin Cancer Res* **9** 2015-21.
- Carboni F, Lepiane P, Santoro R, et al. (2005). Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. *J Surg Oncol* **90** 95-100.
- Carey RW, Hilgenberg AD, Wilkins EW, Jr., et al. (1993). Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. *Cancer Invest* **11** 99-105.
- Carmeliet P, Dor Y, Herbert JM, et al. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. *Nature* **394** 485-90.
- Carnell DM, Smith RE, Daley FM, et al. (2006). An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. *Int J Radiat Oncol Biol Phys* **65** 91-9.
- Caygill CP, Watson A, Lao-Sirieix P, et al. (2004). Barrett's oesophagus and adenocarcinoma. *World J Surg Oncol* **2** 12.
- Chandrasoma PT, Der R, Dalton P, et al. (2001). Distribution and significance of epithelial types in columnar-lined esophagus. *Am J Surg Pathol* **25** 1188-93.
- Chandrasoma PT, Der R, Ma Y, et al. (2000). Histology of the gastroesophageal junction: an autopsy study. *Am J Surg Pathol* **24** 402-9.
- Chen J, Rocken C, Hoffmann J, et al. (2005a). Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. *Gut* **54** 920-7.
- Chen WT, Huang CJ, Wu MT, et al. (2005b). Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. *Jpn J Clin Oncol* **35** 207-13.
- Cheng JD and Weiner LM (2003). Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrutumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. *Clin. Cancer Res.*, 9: 1639-1647, 2003. *Clin Cancer Res* **9** 1590-5.
- Cheng KK, Sharp L, McKinney PA, et al. (2000). A case-control study of oesophageal adenocarcinoma in women: a preventable disease. *Br J Cancer* **83** 127-32.
- Cheong JH, Hyung WJ, Chen J, et al. (2004). Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. *Gynecol Oncol* **94** 477-82.
- Chi JT, Wang Z, Nuyten DS, et al. (2006). Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers. *PLoS Med* **3** e47.

- Choi JY, Jang HJ, Shim YM, et al. (2004). 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. *J Nucl Med* **45** 1843-50.
- Chow WH, Blaser MJ, Blot WJ, et al. (1998). An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. *Cancer Res* **58** 588-90.
- Christie NA, Rice TW, DeCamp MM, et al. (1999). M1a/M1b esophageal carcinoma: clinical relevance. *J Thorac Cardiovasc Surg* **118** 900-7.
- Clark GW, Peters JH, Ireland AP, et al. (1994). Nodal metastasis and sites of recurrence after en bloc esophagectomy for adenocarcinoma. *Ann Thorac Surg* **58** 646-53; discussion 653-4.
- Corley DA, Levin TR, Habel LA, et al. (2002). Surveillance and survival in Barrett's adenocarcinomas: a population-based study. *Gastroenterology* **122** 633-40.
- Correa P (1988). A human model of gastric carcinogenesis. *Cancer Res* **48** 3554-60.
- Correa P (2004). Is gastric cancer preventable? *Gut* **53** 1217-9.
- Costa A, Coradini D, Carrassi A, et al. (2001). Re: Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis. *J Natl Cancer Inst* **93** 1175-7.
- Couvelard A, Paraf F, Gratio V, et al. (2000). Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. *J Pathol* **192** 14-8.
- Craanen ME, Dekker W, Blok P, et al. (1992). Time trends in gastric carcinoma: changing patterns of type and location. *Am J Gastroenterol* **87** 572-9.
- Cunningham D, Allum WH and S.P. S (2005a). Perioperative chemotherapy in operable gastric and lower esophageal cancer. Final results of a randomised controlled trial (the MAGIC trial ISRCTN 937993971). *Proc Am Soc Clin Oncol* **23** 4001.
- Cunningham SC, Kamangar F, Kim MP, et al. (2005b). Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. *J Gastrointest Surg* **9** 718-25.
- Cuschieri A, Talbot IC and Weeden S (2002). Influence of pathological tumour variables on long-term survival in resectable gastric cancer. *Br J Cancer* **86** 674-9.
- Cuschieri A, Weeden S, Fielding J, et al. (1999). Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. *Br J Cancer* **79** 1522-30.
- Dales JP, Garcia S, Meunier-Carpentier S, et al. (2005). Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. *Int J Cancer* **116** 734-739.
- Dalgleish AG and O'Byrne K (2006). Inflammation and cancer: the role of the immune response and angiogenesis. *Cancer Treat Res* **130** 1-38.
- Danson S, Ferry D, Alakhov V, et al. (2004). Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. *Br J Cancer* **90** 2085-91.
- Davessar K, Pezzullo JC, Kessimian N, et al. (1990). Gastric adenocarcinoma: prognostic significance of several pathologic parameters and histologic classifications. *Hum Pathol* **21** 325-32.
- de Hoyos A, Litle VR and Luketich JD (2005). Minimally invasive esophagectomy. *Surg Clin North Am* **85** 631-47.
- de Manzoni G, Pedrazzani C, Verlato G, et al. (2004). Comparison of old and new TNM systems for nodal staging in adenocarcinoma of the gastro-oesophageal junction. *Br J Surg* **91** 296-303.
- Desai AM, Pareek M, Nightingale PG, et al. (2004). Improving outcomes in gastric cancer over 20 years. *Gastric Cancer* **7** 196-201; discussion 201-203.
- Devesa SS, Blot WJ and Fraumeni JF, Jr. (1998). Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *Cancer* **83** 2049-53.
- Devesa SS and Fraumeni JF, Jr. (1999). The rising incidence of gastric cardia cancer. *J Natl Cancer Inst* **91** 747-9.
- Dexter SP, Sue-Ling H, McMahan MJ, et al. (2001). Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. *Gut* **48** 667-70.
- Dicken BJ, Saunders LD, Jhangri GS, et al. (2004). Gastric cancer: establishing predictors of biologic behavior with use of population-based data. *Ann Surg Oncol* **11** 629-35.
- Dickson GH, Waters R, Bull J, et al. (2001). Should we continue oesophageal surgery in a district general hospital? A review of 200 consecutive cases. *Ann R Coll Surg Engl* **83** 167-71.
- Dixon MF, Ed. (2000). Minimum dataset for gastric cancer histopathology reports. Standards and minimum datasets for reporting cancers. London, Royal College of Pathologists. [www.rcpath.org.uk](http://www.rcpath.org.uk)

- Dolan K, Morris AI, Gosney JR, et al. (2004). Three different subsite classification systems for carcinomas in the proximity of the GEJ, but is it all one disease? *J Gastroenterol Hepatol* **19** 24-30.
- Dolan K, Sutton R, Walker SJ, et al. (1999). New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. *Br J Cancer* **80** 834-42.
- Dresner SM and Griffin SM (2000). Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. *Br J Surg* **87** 1426-33.
- Dresner SM, Lamb PJ, Bennett MK, et al. (2001). The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. *Surgery* **129** 103-9.
- Driessen A, Nafteux P, Lerut T, et al. (2004). Identical cytokeratin expression pattern CK7+/CK20- in esophageal and cardiac cancer: etiopathological and clinical implications. *Mod Pathol* **17** 49-55.
- Dripps RD, Lamont A and Eckenhoff JE (1961). The role of anesthesia in surgical mortality. *Jama* **178** 261-6.
- Du JR, Jiang Y, Zhang YM, et al. (2003). Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. *World J Gastroenterol* **9** 1604-6.
- Duff SE, Li C, Jeziorska M, et al. (2003). Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. *Br J Cancer* **89** 426-30.
- Dunn BE, Cohen H and Blaser MJ (1997). Helicobacter pylori. *Clin Microbiol Rev* **10** 720-41.
- Durand RE and LePard NE (1994). Modulation of tumor hypoxia by conventional chemotherapeutic agents. *Int J Radiat Oncol Biol Phys* **29** 481-6.
- Edwards MJ, Gable DR, Lentsch AB, et al. (1996). The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. *Ann Surg* **223** 585-9; discussion 589-91.
- Edwards P, Barry JD, Chatterton MC, et al. (2001). Oesophagogastric cancer and surgical subspecialisation: how much work? *Ann R Coll Surg Engl* **83** 30-3.
- Ekstrom AM, Held M, Hansson LE, et al. (2001). Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. *Gastroenterology* **121** 784-91.
- Ekstrom AM, Signorello LB, Hansson LE, et al. (1999). Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. *J Natl Cancer Inst* **91** 786-90.
- El-Omar EM, Carrington M, Chow WH, et al. (2000). Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* **404** 398-402.
- Eloubeidi MA, Desmond R, Arguedas MR, et al. (2002). Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. *Cancer* **95** 1434-43.
- EUROGAST (1993). An international association between Helicobacter pylori infection and gastric cancer. *Lancet* **341** 1359-62.
- Evans SM, Judy KD, Dunphy I, et al. (2004). Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. *Cancer Res* **64** 1886-92.
- Falk GW (2001). Gastroesophageal reflux disease and Barrett's esophagus. *Endoscopy* **33** 109-18.
- Fan XG, Kelleher D, Fan XJ, et al. (1996). Helicobacter pylori increases proliferation of gastric epithelial cells. *Gut* **38** 19-22.
- Farrell F and Lee A (2004). The erythropoietin receptor and its expression in tumor cells and other tissues. *Oncologist* **9 Suppl 5** 18-30.
- Feakins RM, Nickols CD, Bidd H, et al. (2003). Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. *Hum Pathol* **34** 1276-82.
- Feinstein AR, Sosin DM and Wells CK (1985). The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. *N Engl J Med* **312** 1604-8.
- Feith M, Stein HJ, Mueller J, et al. (2004). Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. *Dis Esophagus* **17** 322-7.
- Feldman L, Wang Y, Rhim JS, et al. (2006). Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. *Prostate* **66** 135-45.
- Feng CW, Wang LD, Jiao LH, et al. (2002). Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. *BMC Cancer* **2** 8.
- Fenoglio-Preiser CM, Wang J, Stemmermann GN, et al. (2003). TP53 and gastric carcinoma: a review. *Hum Mutat* **21** 258-70.
- Fillies T, Werkmeister R, van Diest PJ, et al. (2005). HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. *BMC Cancer* **5** 84.

- Flejou JF, Paraf F, Muzeau F, et al. (1994). Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. *J Clin Pathol* **47** 23-6.
- Flucke U, Steinborn E, Dries V, et al. (2003). Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. *Histopathology* **43** 127-34.
- Fogt F, Wellmann A, Urbanski SJ, et al. (2001). Glut-1 expression in dysplastic and regenerative lesions of the colon. *Int J Mol Med* **7** 615-9.
- Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? *J Natl Cancer Inst* **82** 4-6.
- Folkman J, Watson K, Ingber D, et al. (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. *Nature* **339** 58-61.
- Fondevila C, Metges JP, Fuster J, et al. (2004). p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. *Br J Cancer* **90** 206-15.
- Fontana MG, La Pinta M, Moneghini D, et al. (2003). Prognostic value of Goseki histological classification in adenocarcinoma of the cardia. *Br J Cancer* **88** 401-5.
- Foreman D (2002). Counting cancers at the junction - a problem of routine statistics. *Eur J Gastroenterol Hepatol* **14** 99-101.
- Forman D, Sitas F, Newell DG, et al. (1990). Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. *Int J Cancer* **46** 608-11.
- Forones NM, Carvalho AP, Giannotti-Filho O, et al. (2005). Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia. *Arq Gastroenterol* **42** 30-4.
- Fransen GA, Janssen MJ, Muris JW, et al. (2004). Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. *Aliment Pharmacol Ther* **20** 1045-52.
- Fumagilli U (1996). Resective surgery for cancer of thoracic esophagus. Results of a consensus conference of the International Society for Diseases of the Esophagus. *Dis Esophagus* **9** (Suppl. 1) 30-38.
- Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, et al. (2004). Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. *Mod Pathol* **17** 579-87.
- Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. (2001). *Gut* **49** 347-53.
- Gatenby RA, Coia LR, Richter MP, et al. (1985). Oxygen tension in human tumors: in vivo mapping using CT-guided probes. *Radiology* **156** 211-4.
- Giatromanolaki A, Koukourakis MI, Sivridis E, et al. (2001). Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. *Br J Cancer* **85** 881-90.
- Giatromanolaki A, Sivridis E, Fiska A, et al. (2006). Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas. *Appl Immunohistochem Mol Morphol* **14** 78-82.
- Giatromanolaki A, Sivridis E, Kouskousis C, et al. (2003). Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. *Melanoma Res* **13** 493-501.
- Gill PG, Denham JW, Jamieson GG, et al. (1992). Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. *J Clin Oncol* **10** 1037-43.
- Gillison EW, Powell J, McConkey CC, et al. (2002). Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia. *Br J Surg* **89** 344-8.
- Goethals L, Debucquoy A, Perneel C, et al. (2006a). Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers. *Int J Radiat Oncol Biol Phys* **65** 246-54.
- Goethals L, Perneel C, Debucquoy A, et al. (2006b). A new approach to the validation of tissue microarrays. *J Pathol* **208** 607-14.
- Goodwin CS and Worsley BW (1993). Microbiology of Helicobacter pylori. *Gastroenterol Clin North Am* **22** 5-19.
- Goseki N, Maruyama M, Takizawa T, et al. (1995). Morphological changes in gastric carcinoma with progression. *J Gastroenterol* **30** 287-94.
- Gossot D, Toledo L and Cortes A (2000). Minimal access esophagectomy: where are we up to? *Semin Laparosc Surg* **7** 2-8.

- Gothie E, Richard DE, Berra E, et al. (2000). Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. *J Biol Chem* **275** 6922-7.
- Graham DY (2003). The changing epidemiology of GERD: geography and Helicobacter pylori. *Am J Gastroenterol* **98** 1462-70.
- Graham DY and Yamaoka Y (1998). H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. *Helicobacter* **3** 145-51.
- Grau C and Overgaard J (1992). Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ. *Cancer Chemother Pharmacol* **30** 277-80.
- Gray LH, Conger AD, Ebert M, et al. (1953). The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. *Br J Radiol* **26** 638-48.
- Greijer AE and van der Wall E (2004). The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. *J Clin Pathol* **57** 1009-14.
- Griffin SM (2005). Gastric cancer in the East: same disease, different patient. *Br J Surg* **92** 1055-6.
- Griffin SM, Bowrey DJ and Allum WH (2005). Upper gastrointestinal surgeons comment on NICE dyspepsia guidelines. *Bmj* **330** 308-9.
- Griffiths EA, Pritchard SA, Welch IM, et al. (2005). Is the hypoxia-inducible factor pathway important in gastric cancer? *Eur J Cancer* **41** 2792-805.
- Gruber G, Greiner RH, Hlushchuk R, et al. (2004). Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? *Breast Cancer Res* **6** R191-8.
- Guidance on Commissioning Cancer Services: Improving Outcomes in Upper Gastrointestinal Cancers. (2001). London, Department of Health.
- Guindi M and Riddell RH (2003). Histology of Barrett's esophagus and dysplasia. *Gastrointest Endosc Clin N Am* **13** 349-68, viii.
- Gulmann C, Grace A, Leader M, et al. (2003). Adenomatous polyposis coli gene, beta-catenin, and E-cadherin expression in proximal and distal gastric cancers and precursor lesions: an immunohistochemical study using tissue microarrays. *Appl Immunohistochem Mol Morphol* **11** 230-7.
- Gulmann C, Hegarty H, Grace A, et al. (2004). Differences in proximal (cardia) versus distal (antral) gastric carcinogenesis via the retinoblastoma pathway. *World J Gastroenterol* **10** 17-21.
- Gulmann C, Lantuejoul S, Grace A, et al. (2005). Telomerase activity in proximal and distal gastric neoplastic and preneoplastic lesions using immunohistochemical detection of hTERT. *Dig Liver Dis* **37** 439-45.
- Gut MO, Parkkila S, Vernerova Z, et al. (2002). Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. *Gastroenterology* **123** 1889-903.
- Hanahan D and Weinberg RA (2000). The hallmarks of cancer. *Cell* **100** 57-70.
- Hansson LE, Engstrand L, Nyren O, et al. (1993). Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. *Gastroenterology* **105** 1098-103.
- Harris AL (2002). Hypoxia--a key regulatory factor in tumour growth. *Nat Rev Cancer* **2** 38-47.
- Haugland HK, Vukovic V, Pintilie M, et al. (2002). Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. *Int J Radiat Oncol Biol Phys* **53** 854-61.
- Heath EI, Burtress BA, Heitmiller RF, et al. (2000). Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. *J Clin Oncol* **18** 868-76.
- Heeren PA, Kelder W, Blondeel I, et al. (2005). Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. *Eur J Surg Oncol* **31** 270-6.
- Heeren PA, van Westreenen HL, Geersing GJ, et al. (2004). Influence of tumor characteristics on the accuracy of endoscopic ultrasonography in staging cancer of the esophagus and esophagogastric junction. *Endoscopy* **36** 966-71.
- Heitmiller RF (1992). Results of standard left thoracoabdominal esophagogastric resection. *Semin Thorac Cardiovasc Surg* **4** 314-9.
- Hermanek P, Altendorf-Hofmann A, Mansmann U, et al. (1998). Improvements in staging of gastric carcinoma from using the new edition of TNM classification. *Eur J Surg Oncol* **24** 536-41.
- Hermanek P and Wittekind C (1994). The pathologist and the residual tumor (R) classification. *Pathol Res Pract* **190** 115-23.
- Herskovic A, Martz K, al-Sarraf M, et al. (1992). Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* **326** 1593-8.
- Hockel M, Knoop C, Schlenger K, et al. (1993). Intratumoral pO<sub>2</sub> predicts survival in advanced cancer of the uterine cervix. *Radiother Oncol* **26** 45-50.



- Hockel M, Schlenger K, Aral B, et al. (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. *Cancer Res* **56** 4509-15.
- Hockel M, Schlenger K, Knoop C, et al. (1991). Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O<sub>2</sub> tension measurements. *Cancer Res* **51** 6098-102.
- Hockel M and Vaupel P (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *J Natl Cancer Inst* **93** 266-76.
- Hofstetter W, Swisher SG, Correa AM, et al. (2002). Treatment outcomes of resected esophageal cancer. *Ann Surg* **236** 376-84; discussion 384-5.
- Holscher AH, Bollschweiler E, Bumm R, et al. (1995). Prognostic factors of resected adenocarcinoma of the esophagus. *Surgery* **118** 845-55.
- Horsman MR and Overgaard J (1992). Overcoming tumour radiation resistance resulting from acute hypoxia. *Eur J Cancer* **28A** 717-8.
- Hoskin PJ, Sibtain A, Daley FM, et al. (2003). GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. *Br J Cancer* **89** 1290-7.
- Howson CP, Hiyama T and Wynder EL (1986). The decline in gastric cancer: epidemiology of an unplanned triumph. *Epidemiol Rev* **8** 1-27.
- Hu CJ, Wang LY, Chodosh LA, et al. (2003). Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. *Mol Cell Biol* **23** 9361-74.
- Huang SP, Wu MS, Shun CT, et al. (2005). Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. *J Biomed Sci* **12** 229-41.
- Huang TJ, Wang JY, Lin SR, et al. (2001). Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features. *Acta Oncol* **40** 638-43.
- Hui EP, Chan AT, Pezzella F, et al. (2002). Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. *Clin Cancer Res* **8** 2595-604.
- Hulscher JB, van Sandick JW, de Boer AG, et al. (2002). Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. *N Engl J Med* **347** 1662-9.
- Hutchison GJ, Valentine HR, Loncaster JA, et al. (2004). Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. *Clin Cancer Res* **10** 8405-12.
- Hyung WJ, Lee JH, Choi SH, et al. (2002). Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. *Ann Surg Oncol* **9** 562-7.
- IARC monograph on the evaluation of carcinogenic risks to humans: schistosomes, liver flukes and *Helicobacter pylori*. (1994). Lyon, IARC.
- Iatropoulos MJ and Williams GM (1996). Proliferation markers. *Exp Toxicol Pathol* **48** 175-81.
- Ichikura T, Ogawa T, Kawabata T, et al. (2003). Is adenocarcinoma of the gastric cardia a distinct entity independent of subcardial carcinoma? *World J Surg* **27** 334-8.
- Ichikura T, Tomimatsu S, Ohkura E, et al. (2001). Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. *J Surg Oncol* **78** 132-7.
- Iftikhar SY, Steele RJ, Watson S, et al. (1992). Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus. *Gut* **33** 733-7.
- Igaki H, Kato H, Tachimori Y, et al. (2001). Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection. *Eur J Cardiothorac Surg* **19** 887-93.
- Ikeguchi M, Katano K, Oka A, et al. (1996). The proliferative activity of cancer cells at the invasive margin of a tumor is a good indicator of the prognosis of patients with gastric cancer with serosal invasion. *Int Surg* **81** 122-5.
- Ikeguchi M, Oka S, Gomyo Y, et al. (2001). Postoperative morbidity and mortality after gastrectomy for gastric carcinoma. *Hepatogastroenterology* **48** 1517-20.
- Isono K, Sato H and Nakayama K (1991). Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. *Oncology* **48** 411-20.
- Ito M, Tanaka S, Kim S, et al. (2003). The specific expression of hypoxia inducible factor-1alpha in human gastric mucosa induced by nonsteroidal anti-inflammatory drugs. *Aliment Pharmacol Ther* **18 Suppl 1** 90-8.
- Izbicki JR, Hosch SB, Pichlmeier U, et al. (1997). Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. *N Engl J Med* **337** 1188-94.
- Jain RK (1994). Barriers to drug delivery in solid tumors. *Sci Am* **271** 58-65.



- Jamieson GG, Mathew G, Ludemann R, et al. (2004). Postoperative mortality following oesophagectomy and problems in reporting its rate. *Br J Surg* **91** 943-7.
- Jankowski JA, Harrison RF, Perry I, et al. (2000). Barrett's metaplasia. *Lancet* **356** 2079-85.
- Jenkins GJ, Doak SH, Parry JM, et al. (2002). Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. *Br J Surg* **89** 824-37.
- Jimenez P, Piazuelo E, Sanchez MT, et al. (2005). Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. *World J Gastroenterol* **11** 2697-703.
- Johansson J, DeMeester TR, Hagen JA, et al. (2004). En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus. *Arch Surg* **139** 627-31; discussion 631-3.
- Johansson J and Walther B (2000). Clinical outcome and long-term survival rates after esophagectomy are not determined by age over 70 years. *J Gastrointest Surg* **4** 55-62.
- Jones MK, Szabo IL, Kawanaka H, et al. (2002). von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. *Faseb J* **16** 264-6.
- Jubb AM, Pham TQ, Hanby AM, et al. (2004). Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. *J Clin Pathol* **57** 504-12.
- Kaanders JH, Wijffels KI, Marres HA, et al. (2002). Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. *Cancer Res* **62** 7066-74.
- Kajiyama Y, Tsurumaru M, Udagawa H, et al. (1997). Prognostic factors in adenocarcinoma of the gastric cardia: pathologic stage analysis and multivariate regression analysis. *J Clin Oncol* **15** 2015-21.
- Kapoor N, Bassi A, Sturges R, et al. (2005). Predictive value of alarm features in a rapid access upper gastrointestinal cancer service. *Gut* **54** 40-5.
- Karaczyn A, Ivanov S, Reynolds M, et al. (2006). Ascorbate depletion mediates up-regulation of hypoxia-associated proteins by cell density and nickel. *J Cell Biochem* **97** 1025-35.
- Kato H, Kuwano H, Nakajima M, et al. (2002). Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. *Cancer* **94** 921-8.
- Kattan MW, Karpeh MS, Mazumdar M, et al. (2003). Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. *J Clin Oncol* **21** 3647-50.
- Kawamura T, Kusakabe T, Sugino T, et al. (2001). Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. *Cancer* **92** 634-41.
- Keighley MR (2003). Gastrointestinal cancers in Europe. *Aliment Pharmacol Ther* **18 Suppl 3** 7-30.
- Keller G, Hofler H and Becker KF (2005). Molecular medicine of gastric adenocarcinomas. *Expert Rev Mol Med* **7** 1-13.
- Kelsen DP, Ginsberg R, Pajak TF, et al. (1998). Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. *N Engl J Med* **339** 1979-84.
- Kennedy AS, Raleigh JA, Perez GM, et al. (1997). Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. *Int J Radiat Oncol Biol Phys* **37** 897-905.
- Khan OA, Alexiou C, Soomro I, et al. (2004). Pathological determinants of survival in node-negative oesophageal cancer. *Br J Surg* **91** 1586-91.
- Khan OA, Fitzgerald JJ, Soomro I, et al. (2003). Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer. *Br J Cancer* **88** 1549-52.
- Kikuchi S, Nakajima T, Kobayashi O, et al. (2000). Effect of age on the relationship between gastric cancer and Helicobacter pylori. Tokyo Research Group of Prevention for Gastric Cancer. *Jpn J Cancer Res* **91** 774-9.
- Kim CM, Vocke C, Torres-Cabala C, et al. (2006). Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors. *J Urol* **175** 1908-14.
- Kim JP, Lee JH, Kim SJ, et al. (1998). Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. *Gastric Cancer* **1** 125-133.
- Kim MA, Lee HS, Yang HK, et al. (2005). Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. *Cancer* **103** 1439-46.
- Kim PK, Zamora R, Petrosko P, et al. (2001). The regulatory role of nitric oxide in apoptosis. *Int Immunopharmacol* **1** 1421-41.
- Kim SH, Shin YK, Lee KM, et al. (2003). An improved protocol of biotinylated tyramine-based immunohistochemistry minimizing nonspecific background staining. *J Histochem Cytochem* **51** 129-32.
- Kim WS, Kim YY, Jang SJ, et al. (2000). Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. *J Korean Med Sci* **15** 420-4.

- Kimura S, Kitadai Y, Tanaka S, et al. (2004). Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. *Eur J Cancer* **40** 1904-12.
- King PM, Blazeby JM, Gupta J, et al. (2004). Upper gastrointestinal cancer pathology reporting: a regional audit to compare standards with minimum datasets. *J Clin Pathol* **57** 702-5.
- Koch CJ, Evans SM and Lord EM (1995). Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. *Br J Cancer* **72** 869-74.
- Koea JB, Karpeh MS and Brennan MF (2000). Gastric cancer in young patients: demographic, clinicopathological, and prognostic factors in 92 patients. *Ann Surg Oncol* **7** 346-51.
- Komukai S, Nishimaki T, Watanabe H, et al. (2000). Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. *Surgery* **127** 40-6.
- Kondo K, Klco J, Nakamura E, et al. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. *Cancer Cell* **1** 237-46.
- Konerding MA, Malkusch W, Klapthor B, et al. (1999). Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. *Br J Cancer* **80** 724-32.
- Kooby DA, Suriawinata A, Klimstra DS, et al. (2003). Biologic predictors of survival in node-negative gastric cancer. *Ann Surg* **237** 828-35; discussion 835-7.
- Koong AC, Mehta VK, Le QT, et al. (2000). Pancreatic tumors show high levels of hypoxia. *Int J Radiat Oncol Biol Phys* **48** 919-22.
- Korkolopoulou P, Patsouris E, Konstantinidou AE, et al. (2004). Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. *Neuropathol Appl Neurobiol* **30** 267-78.
- Korst RJ (2005). Surgical resection for esophageal carcinoma: speaking the language. *World J Gastroenterol* **11** 2211-2.
- Koshiji M, To KK, Hammer S, et al. (2005). HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. *Mol Cell* **17** 793-803.
- Koukourakis MI, Giatromanolaki A, Sivridis E, et al. (2000). Cancer vascularization: implications in radiotherapy? *Int J Radiat Oncol Biol Phys* **48** 545-53.
- Koukourakis MI, Giatromanolaki A, Sivridis E, et al. (2004). Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. *Int J Radiat Oncol Biol Phys* **59** 67-71.
- Koukourakis MI, Giatromanolaki A, Sivridis E, et al. (2002). Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. *Int J Radiat Oncol Biol Phys* **53** 1192-202.
- Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. (2001). Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. *Cancer Res* **61** 1830-2.
- Krishnadath KK, Tilanus HW, van Blankenstein M, et al. (1997). Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. *J Pathol* **182** 331-8.
- Kumar SM, Acs G, Fang D, et al. (2005). Functional erythropoietin autocrine loop in melanoma. *Am J Pathol* **166** 823-30.
- Kunisaki C, Akiyama H, Nomura M, et al. (2005). Developing an appropriate staging system for esophageal carcinoma. *J Am Coll Surg* **201** 884-90.
- Kurokawa T, Miyamoto M, Kato K, et al. (2003). Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. *Br J Cancer* **89** 1042-7.
- Kuwai T, Kitadai Y, Tanaka S, et al. (2003). Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. *Int J Cancer* **105** 176-81.
- Lagarde SM, Cense HA, Hulscher JB, et al. (2005). Prospective analysis of patients with adenocarcinoma of the gastric cardia and lymph node metastasis in the proximal field of the chest. *Br J Surg* **92** 1404-8.
- Lagergren J, Bergstrom R, Lindgren A, et al. (1999a). Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* **340** 825-31.
- Lagergren J, Bergstrom R and Nyren O (1999b). Association between body mass and adenocarcinoma of the esophagus and gastric cardia. *Ann Intern Med* **130** 883-90.
- Langley SM, Alexiou C, Bailey DH, et al. (2002). The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma. *Ann Thorac Surg* **73** 1704-9.

- Lartigau E, Randrianarivelo H, Avril MF, et al. (1997). Intratumoral oxygen tension in metastatic melanoma. *Melanoma Res* **7** 400-6.
- Lauren P (1965). The Two Histological Main Types Of Gastric Carcinoma: Diffuse And So-Called Intestinal-Type Carcinoma. An Attempt At A Histo-Clinical Classification. *Acta Pathol Microbiol Scand* **64** 31-49.
- Lauren PA and Nevalainen TJ (1993). Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. *Cancer* **71** 2926-33.
- Law S, Arcilla C, Chu KM, et al. (1998). The significance of histologically infiltrated resection margin after esophagectomy for esophageal cancer. *Am J Surg* **176** 286-90.
- Lee HK, Yang HK, Kim WH, et al. (2001). Influence of the number of lymph nodes examined on staging of gastric cancer. *Br J Surg* **88** 1408-12.
- Lee HS, Lee HK, Kim HS, et al. (2003). Tumour suppressor gene expression correlates with gastric cancer prognosis. *J Pathol* **200** 39-46.
- Leppilampi M, Saarnio J, Karttunen TJ, et al. (2003). Carbonic anhydrase isozymes IX and XII in gastric tumors. *World J Gastroenterol* **9** 1398-403.
- Lerut T, Nafteux P, Moons J, et al. (2005). Quality in the surgical treatment of cancer of the esophagus and gastroesophageal junction. *Eur J Surg Oncol* **31** 587-94.
- Leung WK, Yu J, To KF, et al. (2001). Apoptosis and proliferation in Helicobacter pylori-associated gastric intestinal metaplasia. *Aliment Pharmacol Ther* **15** 1467-72.
- Levine DS, Haggitt RC, Blount PL, et al. (1993). An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. *Gastroenterology* **105** 40-50.
- Lewis I (1946). The surgical treatment of carcinoma of the oesophagus with special reference to a new operation for growths of the middle third. *Br J Surg* **34** 18-31.
- Li LG and Xu HM (2005). Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. *World J Gastroenterol* **11** 2539-44.
- Li YH, Wang C, Meng K, et al. (2004). Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. *World J Gastroenterol* **10** 1984-8.
- Lidgren A, Hedberg Y, Grankvist K, et al. (2005). The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. *Clin Cancer Res* **11** 1129-35.
- Lin J and Iannettoni MD (2005). Transhiatal esophagectomy. *Surg Clin North Am* **85** 593-610.
- Liu DH, Zhang XY, Fan DM, et al. (2001). Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma. *World J Gastroenterol* **7** 500-5.
- Liu XH, Kirschenbaum A, Lu M, et al. (2002). Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. *J Biol Chem* **277** 50081-6.
- Lord RV, Park JM, Wickramasinghe K, et al. (2003). Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. *J Thorac Cardiovasc Surg* **125** 246-53.
- Lorinc E, Jakobsson B, Landberg G, et al. (2005). Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus. *Histopathology* **46** 642-8.
- Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. (2003). Minimally invasive esophagectomy: outcomes in 222 patients. *Ann Surg* **238** 486-94; discussion 494-5.
- Lynch HT, Grady W, Suriano G, et al. (2005). Gastric cancer: new genetic developments. *J Surg Oncol* **90** 114-33; discussion 133.
- Macdonald JS, Smalley SR, Benedetti J, et al. (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* **345** 725-30.
- Maeda H and Akaike T (1998). Nitric oxide and oxygen radicals in infection, inflammation, and cancer. *Biochemistry (Mosc)* **63** 854-65.
- Maeda K, Chung YS, Ogawa Y, et al. (1996). Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. *Cancer* **77** 858-63.
- Maeda K, Kang SM, Onoda N, et al. (1999). Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. *Cancer* **86** 566-71.
- Maehara Y, Hasuda S, Koga T, et al. (2000). Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. *Br J Surg* **87** 353-7.
- Mannick EE, Bravo LE, Zarama G, et al. (1996). Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. *Cancer Res* **56** 3238-43.

- Mapstone N, Ed. (1998). Minimum dataset for oesophageal carcinoma histopathology reports. London, Royal College of Pathologists. [www.rcpath.org.uk](http://www.rcpath.org.uk)
- Marchildon PA, Ciota LM, Zamaniyan FZ, et al. (1996). Evaluation of three commercial enzyme immunoassays compared with the <sup>13</sup>C urea breath test for detection of Helicobacter pylori infection. *J Clin Microbiol* **34** 1147-52.
- Mariette C, Balon JM, Piessen G, et al. (2003). Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. *Cancer* **97** 1616-23.
- Maruyama K, Gunven P, Okabayashi K, et al. (1989). Lymph node metastases of gastric cancer. General pattern in 1931 patients. *Ann Surg* **210** 596-602.
- Maruyama K, Sasako M, Kinoshita T, et al. (1996). Surgical treatment for gastric cancer: the Japanese approach. *Semin Oncol* **23** 360-8.
- Matsuzo K, Segade F, Matsuzo U, et al. (2004). Differential expression of glucose transporters in normal and pathologic thyroid tissue. *Thyroid* **14** 806-12.
- Maxwell PH, Pugh CW and Ratcliffe PJ (2001). Activation of the HIF pathway in cancer. *Curr Opin Genet Dev* **11** 293-9.
- Maxwell PH, Wiesener MS, Chang GW, et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* **399** 271-5.
- Mayer A, Wree A, Hockel M, et al. (2004). Lack of correlation between expression of HIF-1 alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. *Cancer Res* **64** 5876-81.
- Maynard MA, Qi H, Chung J, et al. (2003). Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. *J Biol Chem* **278** 11032-40.
- McAteer D, Wallis F, Couper G, et al. (1999). Evaluation of <sup>18</sup>F-FDG positron emission tomography in gastric and oesophageal carcinoma. *Br J Radiol* **72** 525-9.
- McBroom JW, Acs G, Rose GS, et al. (2005). Erythropoietin receptor function and expression in epithelial ovarian carcinoma. *Gynecol Oncol* **99** 571-7.
- McCulloch P (1994). Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980-1985. *Br J Surg* **81** 417-20.
- McCulloch P, Niita ME, Kazi H, et al. (2005). Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. *Br J Surg* **92** 5-13.
- McCulloch P, Taggart T, Ochiai A, et al. (1997). c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. *Eur J Surg Oncol* **23** 304-9.
- McCulloch P, Ward J and Tekkis PP (2003). Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. *Bmj* **327** 1192-7.
- McKeown KC (1976). Total three-stage oesophagectomy for cancer of the oesophagus. *Br J Surg* **63** 259-62.
- McLeod HL and Murray GI (1999). Tumour markers of prognosis in colorectal cancer. *Br J Cancer* **79** 191-203.
- McShane LM, Altman DG, Sauerbrei W, et al. (2005). REporting recommendations for tumour MARKer prognostic studies (REMARK). *Br J Cancer* **93** 387-91.
- Melville A, Morris E, Forman D, et al. (2001). Management of upper gastrointestinal cancers. *Qual Health Care* **10** 57-64.
- Meng H, Lu C, Mabuchi H, et al. (2004). Prognostic significance and different properties of survivin splicing variants in gastric cancer. *Cancer Lett* **216** 147-55.
- Merchant NB, Guillem JG, Paty PB, et al. (1999). T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. *J Gastrointest Surg* **3** 642-7.
- Metzen E, Zhou J, Jelkmann W, et al. (2003). Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. *Mol Biol Cell* **14** 3470-81.
- Metzger R, Bollschweiler E, Vallbohmer D, et al. (2004). High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? *Dis Esophagus* **17** 310-4.
- Meyer HJ (2005). The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer. *Eur J Surg Oncol* **31** 595-604.
- Ming SC (1977). Gastric carcinoma. A pathobiological classification. *Cancer* **39** 2475-85.
- Mobius C, Stein HJ, Becker I, et al. (2003). The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma. *Eur J Surg Oncol* **29** 890-4.
- Mochiki E, Kuwano H, Katoh H, et al. (2004). Evaluation of <sup>18</sup>F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. *World J Surg* **28** 247-53.
- Monig S, Baldus SE, Collet PH, et al. (2001). Histological grading in gastric cancer by Goseki classification: correlation with histopathological subtypes and prognosis. *Anticancer Res* **21** 617-20.

- Montgomery E, Bronner MP, Goldblum JR, et al. (2001). Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. *Hum Pathol* **32** 368-78.
- Morales CP, Souza RF and Spechler SJ (2002). Hallmarks of cancer progression in Barrett's oesophagus. *Lancet* **360** 1587-9.
- Morris CD, Armstrong GR, Bigley G, et al. (2001). Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. *Am J Gastroenterol* **96** 990-6.
- Movsas B, Chapman JD, Hanlon AL, et al. (2001). Hypoxia in human prostate carcinoma: an Eppendorf PO2 study. *Am J Clin Oncol* **24** 458-61.
- MRC (2002). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. *Lancet* **359** 1727-33.
- Msika S, Benhamiche AM, Jouve JL, et al. (2000). Prognostic factors after curative resection for gastric cancer. A population-based study. *Eur J Cancer* **36** 390-6.
- Mullaney PJ, Wadley MS, Hyde C, et al. (2002). Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra la Cancrum/American Joint Committee on Cancer. *Br J Surg* **89** 1405-8.
- Mulligan ED, Dunne B, Griffin M, et al. (2004). Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. *Eur J Surg Oncol* **30** 313-7.
- Munson JL and O'Mahony R (2005). Radical gastrectomy for cancer of the stomach. *Surg Clin North Am* **85** 1021-32, vii.
- Murray GI, Duncan ME, O'Neil P, et al. (1998). Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. *J Pathol* **185** 256-61.
- Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. (2002). Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. *Am J Surg Pathol* **26** 350-7.
- Nakamura T, Ide H, Eguchi R, et al. (2002). Clinical implications of lymph node micrometastasis in patients with histologically node-negative (pN0) esophageal carcinoma. *J Surg Oncol* **79** 224-9.
- Nakanishi K, Hiroi S, Tominaga S, et al. (2005). Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. *Clin Cancer Res* **11** 2583-90.
- Nanthakumaran S, Fernandes E, Thompson AM, et al. (2005). Morbidity and mortality rates following gastric cancer surgery and contiguous organ removal, a population based study. *Eur J Surg Oncol*.
- Nardone G, Rocco A and Malfertheiner P (2004). Review article: helicobacter pylori and molecular events in precancerous gastric lesions. *Aliment Pharmacol Ther* **20** 261-70.
- Naumann M and Crabtree JE (2004). Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis. *Trends Microbiol* **12** 29-36.
- Naunheim KS, Petruska PJ, Roy TS, et al. (1995). Multimodality therapy for adenocarcinoma of the esophagus. *Ann Thorac Surg* **59** 1085-90; discussion 1090-1.
- Newaishy GA, Read GA, Duncan W, et al. (1982). Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. *Clin Radiol* **33** 347-52.
- Newnham A, Quinn MJ, Babb P, et al. (2003). Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-1998. *Aliment Pharmacol Ther* **17** 665-76.
- Newsholme EA and Board M (1991). Application of metabolic-control logic to fuel utilization and its significance in tumor cells. *Adv Enzyme Regul* **31** 225-46.
- Nguyen NT, Gelfand D, Stevens CM, et al. (2004). Current status of minimally invasive esophagectomy. *Minerva Chir* **59** 437-46.
- NICE (2004). Dyspepsia: managing dyspepsia in adults in primary care. London, NICE.
- Nichols FC, 3rd, Allen MS, Deschamps C, et al. (2005). Ivor Lewis esophagogastrectomy. *Surg Clin North Am* **85** 583-92.
- Nigro JJ, DeMeester SR, Hagen JA, et al. (1999). Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. *J Thorac Cardiovasc Surg* **117** 960-8.
- Nishida T, Tanaka S, Haruma K, et al. (1995). Histologic grade and cellular proliferation at the deepest invasive portion correlate with the high malignancy of submucosal invasive gastric carcinoma. *Oncology* **52** 340-6.
- Noda N, Sasako M, Yamaguchi N, et al. (1998). Ignoring small lymph nodes can be a major cause of staging error in gastric cancer. *Br J Surg* **85** 831-4.
- Noguchi Y, Marat D, Saito A, et al. (1999). Expression of facilitative glucose transporters in gastric tumors. *Hepatogastroenterology* **46** 2683-9.

- Nordsmark M, Bentzen SM and Overgaard J (1994). Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. *Acta Oncol* **33** 383-9.
- Nordsmark M, Bentzen SM, Rudat V, et al. (2005). Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. *Radiother Oncol* **77** 18-24.
- Nordsmark M, Loncaster J, Aquino-Parsons C, et al. (2003). Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. *Radiother Oncol* **67** 35-44.
- Nordsmark M, Loncaster J, Chou SC, et al. (2001). Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. *Int J Radiat Oncol Biol Phys* **49** 581-6.
- Nozoe T, Kimura Y, Ishida M, et al. (2002). Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. *Eur J Surg Oncol* **28** 396-400.
- O'Rourke JF, Dachs GU, Gleadle JM, et al. (1997). Hypoxia response elements. *Oncol Res* **9** 327-32.
- Obst B, Wagner S, Sewing KF, et al. (2000). Helicobacter pylori causes DNA damage in gastric epithelial cells. *Carcinogenesis* **21** 1111-5.
- Okawa T, Kita M, Tanaka M, et al. (1989). Results of radiotherapy for inoperable locally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* **17** 49-54.
- Olapade-Olaopa EO, Ogunbiyi JO, MacKay EH, et al. (2001). Further characterization of storage-related alterations in immunoreactivity of archival tissue sections and its implications for collaborative multicenter immunohistochemical studies. *Appl Immunohistochem Mol Morphol* **9** 261-6.
- Olive PL, Aquino-Parsons C, MacPhail SH, et al. (2001a). Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. *Cancer Res* **61** 8924-9.
- Olive PL, Banath JP and Aquino-Parsons C (2001b). Measuring hypoxia in solid tumours--is there a gold standard? *Acta Oncol* **40** 917-23.
- Olmos JA, Rios H and Higa R (2000). Prevalence of Helicobacter pylori infection in Argentina: results of a nationwide epidemiologic study. Argentinean Hp Epidemiologic Study Group. *J Clin Gastroenterol* **31** 33-7.
- Olyae M, Sontag S, Salman W, et al. (1995). Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus. *Gut* **37** 168-73.
- Ormsby AH, Petras RE, Henricks WH, et al. (2002). Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. *Gut* **51** 671-6.
- Orringer MB, Marshall B and Stirling MC (1993). Transhiatal esophagectomy for benign and malignant disease. *J Thorac Cardiovasc Surg* **105** 265-76; discussion 276-7.
- Ott K, Fink U, Becker K, et al. (2003). Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. *J Clin Oncol* **21** 4604-10.
- Overgaard J (1994). Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. *Oncol Res* **6** 509-18.
- Ozuyal S, Ozturk H, Bilgin T, et al. (2005). Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. *Arch Gynecol Obstet* **271** 123-6.
- Palayoor ST, Tofilon PJ and Coleman CN (2003). Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. *Clin Cancer Res* **9** 3150-7.
- Panter SJ, O'Flanagan H, Bramble MG, et al. (2004). Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome. *Aliment Pharmacol Ther* **19** 981-8.
- Parikh D, Johnson M, Chagla L, et al. (1996). D2 gastrectomy: lessons from a prospective audit of the learning curve. *Br J Surg* **83** 1595-9.
- Park DJ, Lee HJ, Kim HH, et al. (2005). Predictors of operative morbidity and mortality in gastric cancer surgery. *Br J Surg* **92** 1099-102.
- Park JH, Kim TY, Jong HS, et al. (2003). Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. *Clin Cancer Res* **9** 433-40.
- Park JW, Chun YS and Kim MS (2004). Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. *J Pharmacol Sci* **94** 221-32.
- Parker C, Milosevic M, Toi A, et al. (2004). Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* **58** 750-7.
- Parkin DM (2001). Global cancer statistics in the year 2000. *Lancet Oncol* **2** 533-43.

- Parkin DM, Bray FI and Devesa SS (2001). Cancer burden in the year 2000. The global picture. *Eur J Cancer* **37 Suppl 8** S4-66.
- Parsonnet J (1995). The incidence of Helicobacter pylori infection. *Aliment Pharmacol Ther* **9 Suppl 2** 45-51.
- Parsonnet J, Friedman GD, Vandersteen DP, et al. (1991). Helicobacter pylori infection and the risk of gastric carcinoma. *N Engl J Med* **325** 1127-31.
- Parsonnet J, Hansen S, Rodriguez L, et al. (1994). Helicobacter pylori infection and gastric lymphoma. *N Engl J Med* **330** 1267-71.
- Pastorekova S, Parkkila S, Parkkila AK, et al. (1997). Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. *Gastroenterology* **112** 398-408.
- Paull A, Trier JS, Dalton MD, et al. (1976). The histologic spectrum of Barrett's esophagus. *N Engl J Med* **295** 476-80.
- Peek RM, Jr. and Blaser MJ (2002). Helicobacter pylori and gastrointestinal tract adenocarcinomas. *Nat Rev Cancer* **2** 28-37.
- Peeters KC, Hundahl SA, Kranenbarg EK, et al. (2005). Low Maruyama Index Surgery for Gastric Cancer: Blinded Reanalysis of the Dutch D1-D2 Trial. *World J Surg.*
- Phull PS, Salmon CA, Park KG, et al. (2006). Age threshold for endoscopy and risk of missing upper gastrointestinal malignancy - data from the Scottish audit of gastric and oesophageal cancer. *Aliment Pharmacol Ther* **23** 229-33.
- Pignatelli B, Bancel B, Esteve J, et al. (1998). Inducible nitric oxide synthase, anti-oxidant enzymes and Helicobacter pylori infection in gastritis and gastric precancerous lesions in humans. *Eur J Cancer Prev* **7** 439-47.
- Pinheiro PS, van der Heijden LH and Coebergh JW (1999). Unchanged survival of gastric cancer in the southeastern Netherlands since 1982: result of differential trends in incidence according to Lauren type and subsite. *Int J Cancer* **84** 28-32.
- Piret JP, Mottet D, Raes M, et al. (2002). Is HIF-1alpha a pro- or an anti-apoptotic protein? *Biochem Pharmacol* **64** 889-92.
- Pohl H and Welch HG (2005). The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. *J Natl Cancer Inst* **97** 142-6.
- Polat A, Cinel L, Dusmez D, et al. (2002). Expression of cell-cycle related proteins in Helicobacter pylori gastritis and association with gastric carcinoma. *Neoplasma* **49** 95-100.
- Polkowski W, Baak JP, van Lanschot JJ, et al. (1998). Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. *J Pathol* **184** 161-8.
- Polkowski W, van Lanschot JJ, Ten Kate FJ, et al. (1995). The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. *Surg Oncol* **4** 163-71.
- Poon RT, Law SY, Chu KM, et al. (1998). Esophagectomy for carcinoma of the esophagus in the elderly: results of current surgical management. *Ann Surg* **227** 357-64.
- Portale G, Peters JH, Hsieh CC, et al. (2005). Can clinical and endoscopic findings accurately predict early-stage adenocarcinoma? *Surg Endosc.*
- Pounder RE and Ng D (1995). The prevalence of Helicobacter pylori infection in different countries. *Aliment Pharmacol Ther* **9 Suppl 2** 33-9.
- Pugh CW, O'Rourke JF, Nagao M, et al. (1997). Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. *J Biol Chem* **272** 11205-14.
- Pye JK, Crumplin MK, Charles J, et al. (2001). One-year survey of carcinoma of the oesophagus and stomach in Wales. *Br J Surg* **88** 278-85.
- Quinn M, Babb P, Brock A, et al. (2001). Cancer trends in England and Wales, 1950-99, London: The Stationary Office.
- Raghunath A, Hungin AP, Wooff D, et al. (2003). Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. *Bmj* **326** 737.
- Rajnakova A, Moochhala S, Goh PM, et al. (2001). Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. *Cancer Lett* **172** 177-85.
- Raleigh JA, Calkins-Adams DP, Rinker LH, et al. (1998). Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. *Cancer Res* **58** 3765-8.
- Raleigh JA, Chou SC, Calkins-Adams DP, et al. (2000). A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. *Clin Cancer Res* **6** 855-62.
- Raleigh JA and Koch CJ (1990). Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. *Biochem Pharmacol* **40** 2457-64.



- Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, et al. (2004). Clinicopathologic characteristics of gastric cancer in a young patient population. *J Gastrointest Surg* **8** 240-4.
- Rampling R, Cruickshank G, Lewis AD, et al. (1994). Direct measurement of pO<sub>2</sub> distribution and bioreductive enzymes in human malignant brain tumors. *Int J Radiat Oncol Biol Phys* **29** 427-31.
- Raouf AA, Evoy DA, Carton E, et al. (2003). Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. *Dis Esophagus* **16** 17-23.
- Reed CE, Mishra G, Sahai AV, et al. (1999). Esophageal cancer staging: improved accuracy by endoscopic ultrasound of celiac lymph nodes. *Ann Thorac Surg* **67** 319-21; discussion 322.
- Reid BJ, Sanchez CA, Blount PL, et al. (1993). Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. *Gastroenterology* **105** 119-29.
- Ribatti D, Marzullo A, Nico B, et al. (2003). Erythropoietin as an angiogenic factor in gastric carcinoma. *Histopathology* **42** 246-50.
- Rice TW, Blackstone EH, Rybicki LA, et al. (2003). Refining esophageal cancer staging. *J Thorac Cardiovasc Surg* **125** 1103-13.
- Rice TW, Falk GW, Achkar E, et al. (1993). Surgical management of high-grade dysplasia in Barrett's esophagus. *Am J Gastroenterol* **88** 1832-6.
- Rice TW, Vargo JJ, Goldblum JR, et al. (2005). Endoscopic ultrasound errors in esophageal cancer. *Am J Gastroenterol* **100** 601-6.
- Riddell RH, Goldman H, Ransohoff DF, et al. (1983). Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Hum Pathol* **14** 931-68.
- Roder JD, Bottcher K, Busch R, et al. (1998). Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. *Cancer* **82** 621-31.
- Roder JD, Busch R, Stein HJ, et al. (1994). Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. *Br J Surg* **81** 410-3.
- Rodriguez Santiago JM, Munoz E, Marti M, et al. (2005). Metastatic lymph node ratio as a prognostic factor in gastric cancer. *Eur J Surg Oncol* **31** 59-66.
- Roh MS, Lee JI and Choi PJ (2004). Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma. *Dis Esophagus* **17** 333-7.
- Roy P, Piard F, Dusserre-Guion L, et al. (1998). Prognostic comparison of the pathological classifications of gastric cancer: a population-based study. *Histopathology* **33** 304-10.
- Ruol A, Parenti A, Zaninotto G, et al. (2000). Intestinal metaplasia is the probable common precursor of adenocarcinoma in barrett esophagus and adenocarcinoma of the gastric cardia. *Cancer* **88** 2520-8.
- Saad RS, El-Gohary Y, Memari E, et al. (2005). Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. *Hum Pathol* **36** 955-61.
- Sabel MS, Smith JL, Nava HR, et al. (2002). Esophageal resection for carcinoma in patients older than 70 years. *Ann Surg Oncol* **9** 210-4.
- Sagar PM, Johnston D, McMahan MJ, et al. (1993). Significance of circumferential resection margin involvement after oesophagectomy for cancer. *Br J Surg* **80** 1386-8.
- SAGOC (2002). Scottish Audit of Gastric and Oesophageal Cancer Report 1997 - 2000. F. J. Gilbert, K. G. M. Park and A. M. Thompson. Edinburgh, The Scottish Executive.
- Sahar DE, Yang GP, Longaker MT, et al. (2005). Surgical application of cDNA microarray technique. *Surgery* **138** 399-403.
- Sakata K, Kwok TT, Murphy BJ, et al. (1991). Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. *Br J Cancer* **64** 809-14.
- Sampliner RE (2002). Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. *Am J Gastroenterol* **97** 1888-95.
- Sato F, Shimada Y, Li Z, et al. (2001). Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. *Br J Surg* **88** 426-32.
- Saukkonen K, Rintahaka J, Sivula A, et al. (2003). Cyclooxygenase-2 and gastric carcinogenesis. *Apmis* **111** 915-25.
- Schindl M, Schoppmann SF, Samonigg H, et al. (2002). Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. *Clin Cancer Res* **8** 1831-7.
- Schmid T, Zhou J and Brune B (2004). HIF-1 and p53: communication of transcription factors under hypoxia. *J Cell Mol Med* **8** 423-31.
- Semenza GL (1999). Regulation of mammalian O<sub>2</sub> homeostasis by hypoxia-inducible factor 1. *Annu Rev Cell Dev Biol* **15** 551-78.

- Semenza GL (2002). HIF-1 and tumor progression: pathophysiology and therapeutics. *Trends Mol Med* **8** S62-7.
- Semenza GL (2003). Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* **3** 721-32.
- Shi H, Xu JM, Hu NZ, et al. (2003). Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. *World J Gastroenterol* **9** 1421-6.
- Shinkai M, Niwa Y, Arisawa T, et al. (2000). Evaluation of prognosis of squamous cell carcinoma of the oesophagus by endoscopic ultrasonography. *Gut* **47** 120-5.
- Siewert JR (2005). Gastric cancer: the dispute between East and West. *Gastric Cancer* **8** 59-61.
- Siewert JR, Bottcher K, Stein HJ, et al. (1998a). Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. *Ann Surg* **228** 449-61.
- Siewert JR, Feith M and Stein HJ (2005). Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. *J Surg Oncol* **90** 139-46; discussion 146.
- Siewert JR, Feith M, Werner M, et al. (2000). Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. *Ann Surg* **232** 353-61.
- Siewert JR, Kestlmeier R, Busch R, et al. (1996). Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. *Br J Surg* **83** 1144-7.
- Siewert JR and Stein HJ (1998b). Classification of adenocarcinoma of the oesophagogastric junction. *Br J Surg* **85** 1457-9.
- Siewert JR, Stein HJ, Feith M, et al. (2001). Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. *Ann Surg* **234** 360-7; discussion 368-9.
- Siu KF, Cheung HC and Wong J (1986). Shrinkage of the esophagus after resection for carcinoma. *Ann Surg* **203** 173-6.
- Sivridis E, Giatromanolaki A, Gatter KC, et al. (2002). Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. *Cancer* **95** 1055-63.
- Sivridis E, Giatromanolaki A and Koukourakis MI (2005). Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. *J Clin Pathol* **58** 1033-8.
- Skinner DB (1983). En bloc resection for neoplasms of the esophagus and cardia. *J Thorac Cardiovasc Surg* **85** 59-71.
- Slevin NJ and Stout R (1989). Carcinoma of the oesophagus--a review of 108 cases treated by radical radiotherapy. *Clin Radiol* **40** 200-3.
- Smith GV and Farthing MJ (2005). The effect of ascorbic acid on Helicobacter pylori induced cyclooxygenase 2 expression and prostaglandin E2 production by gastric epithelial cells in vitro. *Helicobacter* **10** 83-9.
- Sobin LH, Ed. (2002). International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. New York, Wiley-Liss
- Sohda M, Ishikawa H, Masuda N, et al. (2004). Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. *Int J Cancer* **110** 838-44.
- Song ZJ, Gong P and Wu YE (2002). Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. *World J Gastroenterol* **8** 591-5.
- Song ZY, Wen SQ, Peng JP, et al. (2004). Significance of vascular endothelial growth factor expression and its correlation with inducible nitric oxide synthase in gastric cancer. *World J Gastroenterol* **10** 1250-5.
- Songun I, van de Velde CJ, Arends JW, et al. (1999). Classification of gastric carcinoma using the Goseki system provides prognostic information additional to TNM staging. *Cancer* **85** 2114-8.
- Songun I, van de Velde CJ, Hermans J, et al. (1996). Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). *Br J Cancer* **74** 1783-8.
- Sowter HM, Raval RR, Moore JW, et al. (2003). Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. *Cancer Res* **63** 6130-4.
- Spechler SJ and Goyal RK (1996). The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. *Gastroenterology* **110** 614-21.
- Spence GM, Graham AN, Mulholland K, et al. (2004). Bone marrow micrometastases and markers of angiogenesis in esophageal cancer. *Ann Thorac Surg* **78** 1944-9; discussion 1950.

- Steer HW and Colin-Jones DG (1975). Mucosal changes in gastric ulceration and their response to carbenoxolone sodium. *Gut* **16** 590-7.
- Stephens MR, Lewis WG, White S, et al. (2005). Prognostic significance of alarm symptoms in patients with gastric cancer. *Br J Surg* **92** 840-6.
- Stoeltzing O, McCarty MF, Wey JS, et al. (2004). Role of Hypoxia-Inducible Factor 1alpha in Gastric Cancer Cell Growth, Angiogenesis, and Vessel Maturation. *J Natl Cancer Inst* **96** 946-956.
- Streitz JM, Jr., Andrews CW, Jr. and Ellis FH, Jr. (1993). Endoscopic surveillance of Barrett's esophagus. Does it help? *J Thorac Cardiovasc Surg* **105** 383-7; discussion 387-8.
- Streitz JM, Jr., Ellis FH, Jr., Tilden RL, et al. (1998). Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. *Am J Gastroenterol* **93** 911-5.
- Strieth S, Hartschuh W, Pilz L, et al. (2000). Angiogenic switch occurs late in squamous cell carcinomas of human skin. *Br J Cancer* **82** 591-600.
- Sue-Ling HM, Johnston D, Martin IG, et al. (1993). Gastric cancer: a curable disease in Britain. *Bmj* **307** 591-6.
- Suerbaum S and Michetti P (2002). Helicobacter pylori infection. *N Engl J Med* **347** 1175-86.
- Sumpter K, Harper-Wynne C, Cunningham D, et al. (2005). Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. *Br J Cancer* **92** 1976-83.
- Suzuki H, Tomida A and Tsuruo T (2001). Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. *Oncogene* **20** 5779-88.
- Szabo IL, Kawanaka H, Jones MK, et al. (2001). Activation of hypoxia inducible factor-1alpha in gastric mucosa in response to ethanol injury: a trigger for angiogenesis? *Life Sci* **69** 3035-44.
- Tabara H, Kohno H, Dhar DK, et al. (2001). Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients. *Acta Oncol* **40** 622-8.
- Tachibana M, Dhar DK, Kinugasa S, et al. (2000). Esophageal cancer with distant lymph node metastasis: prognostic significance of metastatic lymph node ratio. *J Clin Gastroenterol* **31** 318-22.
- Tachibana M, Dhar DK, Kinugasa S, et al. (2002). Esophageal cancer patients surviving 6 years after esophagectomy. *Langenbecks Arch Surg* **387** 77-83.
- Takahashi R, Tanaka S, Hiyama T, et al. (2003). Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. *Oncol Rep* **10** 797-802.
- Takano Y, Kato Y, van Diest PJ, et al. (2000). Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. *Am J Pathol* **156** 585-94.
- Talks KL, Turley H, Gatter KC, et al. (2000). The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. *Am J Pathol* **157** 411-21.
- Tanimoto K, Yoshiga K, Eguchi H, et al. (2003). Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. *Carcinogenesis* **24** 1779-83.
- Teicher BA (1994). Hypoxia and drug resistance. *Cancer Metastasis Rev* **13** 139-68.
- Theodoropoulos VE, Lazaris A, Sofras F, et al. (2004). Hypoxia-inducible factor 1alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. *Eur Urol* **46** 200-8.
- Theodoropoulos VE, Lazaris AC, Kastriotis I, et al. (2005). Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. *BJU Int* **95** 425-31.
- Thomlinson RH and Gray LH (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. *Br J Cancer* **9** 539-49.
- Thompson AM (2005). Microarray technology for surgeons. *Br J Surg* **92** 387-8.
- Thompson AM, Wright DJ, Murray W, et al. (2004). Analysis of 153 deaths after upper gastrointestinal endoscopy: room for improvement? *Surg Endosc* **18** 22-5.
- Thompson WM (1983). Esophageal cancer. *Int J Radiat Oncol Biol Phys* **9** 1533-65.
- TNM Supplement: A Commentary on Uniform Use (2003). Wiley-Liss.
- Tuccillo C, Cuomo A, Rocco A, et al. (2005). Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. *J Pathol* **207** 277-84.
- Turner JR, Odze RD, Crum CP, et al. (1997). MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. *Hum Pathol* **28** 740-4.

- Uemura N, Okamoto S, Yamamoto S, et al. (2001). Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* **345** 784-9.
- Unruh A, Ressel A, Mohamed HG, et al. (2003). The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. *Oncogene* **22** 3213-20.
- Urano N, Fujiwara Y, Doki Y, et al. (2006). Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. *Gastric Cancer* **9** 44-9.
- Usselman B, Newbold M, Morris AG, et al. (2001). Telomerase activity and patient survival after surgery for gastric and oesophageal cancer. *Eur J Gastroenterol Hepatol* **13** 903-8.
- van Dekken H, Geelen E, Dinjens WN, et al. (1999). Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. *Cancer Res* **59** 748-52.
- van der Woude CJ, Jansen PL, Tiebosch AT, et al. (2002). Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. *Hum Pathol* **33** 686-92.
- van der Woude CJ, Kleibeuker JH, Jansen PL, et al. (2004). Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. *Apoptosis* **9** 123-30.
- van der Woude CJ, Kleibeuker JH, Tiebosch AT, et al. (2003). Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins. *J Clin Pathol* **56** 699-702.
- van Diest PJ, Vleugel MM and van der Wall E (2005). Expression of HIF-1alpha in human tumours. *J Clin Pathol* **58** 335-6.
- Van Trappen PO, Steele D, Lowe DG, et al. (2003). Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. *J Pathol* **201** 544-54.
- Vaupel P (2004). Tumor microenvironmental physiology and its implications for radiation oncology. *Semin Radiat Oncol* **14** 198-206.
- Vaupel P, Schlenger K, Knoop C, et al. (1991). Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O<sub>2</sub> tension measurements. *Cancer Res* **51** 3316-22.
- Vazquez-Sequeiros E, Norton ID, Clain JE, et al. (2001). Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. *Gastrointest Endosc* **53** 751-7.
- Vicari JJ, Peek RM, Falk GW, et al. (1998). The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. *Gastroenterology* **115** 50-7.
- Vieth M, Masoud B, Meining A, et al. (2000). Helicobacter pylori infection: protection against Barrett's mucosa and neoplasia? *Digestion* **62** 225-31.
- Vleugel MM, Greijer AE, Shvarts A, et al. (2005). Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. *J Clin Pathol* **58** 172-7.
- Vogel SB, Mendenhall WM, Sombeck MD, et al. (1995). Downstaging of esophageal cancer after preoperative radiation and chemotherapy. *Ann Surg* **221** 685-93; discussion 693-5.
- Volm M and Koomagi R (2000). Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. *Anticancer Res* **20** 1527-33.
- von Rahden BH, Feith M and Stein HJ (2005a). Carcinoma of the cardia: classification as esophageal or gastric cancer? *Int J Colorectal Dis* **20** 89-93.
- von Rahden BH, Stein HJ, Feith M, et al. (2005b). Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. *J Clin Oncol* **23** 874-9.
- Vyse AJ, Gay NJ, Hesketh LM, et al. (2002). The burden of Helicobacter pylori infection in England and Wales. *Epidemiol Infect* **128** 411-7.
- Wallace MB, Nietert PJ, Earle C, et al. (2002). An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. *Ann Thorac Surg* **74** 1026-32.
- Walsh TN, Noonan N, Hollywood D, et al. (1996). A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. *N Engl J Med* **335** 462-7.
- Wang V, Davis DA, Haque M, et al. (2005). Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. *Cancer Res* **65** 3299-306.
- Wang WH, Huang JQ, Zheng GF, et al. (2003). Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. *J Natl Cancer Inst* **95** 1784-91.
- Wang YQ, Luk JM, Ikeda K, et al. (2004). Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. *Biochem Biophys Res Commun* **317** 358-62.
- Warren JR (1984). Spiral bacteria of the gastric antrum. *Med J Aust* **141** 477-8.

- Wayman J, Dresner SM, Raimes SA, et al. (1999). Transhiatal approach to total gastrectomy for adenocarcinoma of the gastric cardia. *Br J Surg* **86** 536-40.
- Wayman J, Hayes N, Raimes SA, et al. (2000). Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. *Arch Fam Med* **9** 385-8.
- Wendling P, Manz R, Thews G, et al. (1984). Heterogeneous oxygenation of rectal carcinomas in humans: a critical parameter for preoperative irradiation? *Adv Exp Med Biol* **180** 293-300.
- Weston AP, Badr AS, Topalovski M, et al. (2000). Prospective evaluation of the prevalence of gastric *Helicobacter pylori* infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. *Am J Gastroenterol* **95** 387-94.
- Wetscher GJ, Hinder RA, Bagchi D, et al. (1995). Reflux esophagitis in humans is mediated by oxygen-derived free radicals. *Am J Surg* **170** 552-6; discussion 556-7.
- WHO (1977). Histological typing of gastric and oesophageal tumours. International histological classification of tumours, no 18., World Health Organisation.
- Wibe A, Rendedal PR, Svensson E, et al. (2002). Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. *Br J Surg* **89** 327-34.
- Wijnhoven BP, Siersema PD, Hop WC, et al. (1999). Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. *Br J Surg* **86** 529-35.
- Wild CP and Hardie LJ (2003). Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. *Nat Rev Cancer* **3** 676-84.
- Wilson KT, Fu S, Ramanujam KS, et al. (1998). Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. *Cancer Res* **58** 2929-34.
- Wink DA, Vodovotz Y, Laval J, et al. (1998). The multifaceted roles of nitric oxide in cancer. *Carcinogenesis* **19** 711-21.
- Woo KJ, Lee TJ, Park JW, et al. (2006). Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway. *Biochem Biophys Res Commun* **343** 8-14.
- Woods ML, Koch CJ and Lord EM (1996). Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies. *Int J Radiat Oncol Biol Phys* **34** 93-101.
- Wu CW, Hsieh MC, Lo SS, et al. (1996). Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma. *Gut* **38** 525-7.
- Wu MS, Chen CJ and Lin JT (2005). Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. *Cancer Epidemiol Biomarkers Prev* **14** 1878-82.
- Wykoff CC, Beasley NJ, Watson PH, et al. (2000). Hypoxia-inducible expression of tumor-associated carbonic anhydrases. *Cancer Res* **60** 7075-83.
- Yalamarthy S, Witherspoon P, McCole D, et al. (2004). Missed diagnoses in patients with upper gastrointestinal cancers. *Endoscopy* **36** 874-9.
- Yamakawa M, Shiojima K, Takahashi M, et al. (1994). Radiation therapy for esophageal cancer in patients over 80 years old. *Int J Radiat Oncol Biol Phys* **30** 1225-32.
- Yamamoto T, Seino Y, Fukumoto H, et al. (1990). Over-expression of facilitative glucose transporter genes in human cancer. *Biochem Biophys Res Commun* **170** 223-30.
- Yang L, Kuang LG, Zheng HC, et al. (2003). PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma. *World J Gastroenterol* **9** 35-9.
- Yang ZY, Gu XZ, Zhao S, et al. (1983). Long term survival of radiotherapy for esophageal cancer: analysis of 1136 patients surviving for more than 5 years. *Int J Radiat Oncol Biol Phys* **9** 1769-73.
- Yasuda Y, Fujita Y, Matsuo T, et al. (2003). Erythropoietin regulates tumour growth of human malignancies. *Carcinogenesis* **24** 1021-9.
- Ye W, Held M, Lagergren J, et al. (2004). *Helicobacter pylori* infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. *J Natl Cancer Inst* **96** 388-96.
- Ye W and Nyren O (2003). Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. *Gut* **52** 938-41.
- Yeo EJ, Chun YS, Cho YS, et al. (2003). YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. *J Natl Cancer Inst* **95** 516-25.
- Yeung HW, Macapinlac H, Karpel M, et al. (1998). Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. *Clin Positron Imaging* **1** 213-221.

- Yokota T, Kunii Y, Teshima S, et al. (1999). Significant prognostic factors in patients with node-negative gastric cancer. *Int Surg* **84** 331-6.
- Yokota T, Kunii Y, Teshima S, et al. (2000). Significant prognostic factors in patients with early gastric cancer. *Int Surg* **85** 286-90.
- Yoo CH, Noh SH, Kim YI, et al. (1999). Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma. International Union Against Cancer. *World J Surg* **23** 492-7; discussion 497-8.
- Yoshimura H, Dhar DK, Kohno H, et al. (2004). Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. *Clin Cancer Res* **10** 8554-60.
- You WC, Zhang L, Gail MH, et al. (2000). Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. *J Natl Cancer Inst* **92** 1607-12.
- Younes M, Ertan A, Lechago LV, et al. (1997). Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. *Cancer Epidemiol Biomarkers Prev* **6** 303-5.
- Younes M, Lechago J, Chakraborty S, et al. (2000). Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia. *Scand J Gastroenterol* **35** 131-7.
- Younes M, Lechago LV and Lechago J (1996). Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. *Clin Cancer Res* **2** 1151-4.
- Yu CC, Levison DA, Dunn JA, et al. (1995). Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. *Br J Cancer* **71** 1106-10.
- Zafirellis K, Dolan K, Fountoulakis A, et al. (2002). Multivariate analysis of clinical, operative and pathologic features of esophageal cancer: who needs adjuvant therapy? *Dis Esophagus* **15** 155-9.
- Zagzag D, Zhong H, Scalzitti JM, et al. (2000). Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. *Cancer* **88** 2606-18.
- Zhang S, Li L, Lin JY, et al. (2003). Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. *World J Gastroenterol* **9** 899-904.
- Zhang XF, Huang CM, Lu HS, et al. (2004). Surgical treatment and prognosis of gastric cancer in 2,613 patients. *World J Gastroenterol* **10** 3405-8.
- Zhong H, De Marzo AM, Laughner E, et al. (1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. *Cancer Res* **59** 5830-5.
- Zhong H, Semenza GL, Simons JW, et al. (2004). Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. *Cancer Detect Prev* **28** 88-93.
- Zhou YN, Xu CP, Han B, et al. (2002). Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. *World J Gastroenterol* **8** 987-93.